Tedisamil: Difference between revisions

Jump to navigation Jump to search
VisualWikitext
No edit summary
m (Protected "Tedisamil": Bot: Protecting all pages from category Drug ([Edit=Allow only administrators] (indefinite) [Move=Allow only administrators] (indefinite)))
 
(One intermediate revision by one other user not shown)
Line 4: Line 4:
| verifiedrevid = 408916612
| verifiedrevid = 408916612
| IUPAC_name = 3,7-bis(cyclopropylmethyl)-3,7-diazaspiro[bicyclo[3.3.1]nonane-9,1'-cyclopentane]
| IUPAC_name = 3,7-bis(cyclopropylmethyl)-3,7-diazaspiro[bicyclo[3.3.1]nonane-9,1'-cyclopentane]
| image = Tedisamil.svg
| image = Tedisamil.png


<!--Clinical data-->
<!--Clinical data-->
Line 48: Line 48:
| smiles = C1CCC2(C1)C3CN(CC2CN(C3)CC4CC4)CC5CC5
| smiles = C1CCC2(C1)C3CN(CC2CN(C3)CC4CC4)CC5CC5
}}
}}
__NOTOC__
{{SI}}
{{SI}}
{{CMG}}
{{CMG}}
==Overview==
==Overview==
'''Tedisamil''' (3,7-dicyclopropylmethyl-9,9-tetramethylene-3,7-diazabicyclo-3,3,1-nonane) is an experimental class III [[antiarrhythmic]] agent currently being investigated for the treatment of [[atrial fibrillation]]. Tedisamil blocks multiple types of potassium channels in the heart resulting in slowed heart rate. While the effects of tedisamil have been demonstrated in both atrial and ventricular muscle, repolarization is prolonged more efficiently in the atria.<ref name=Hohnloser>{{cite journal|last=Hohnloser|first=S.H.|coauthors=et al.|title=Safety and Efficacy of Intravenously Administered Tedisamil for Rapid Conversion of Recent-Onset Atrial Fibrillation or Atrial Flutter|journal=Am J Cardiol|year=2004|issue=44|pages=99–104}}</ref> Tedisamil is administered intravenously and has a [[half-life]] of approximately 8 –13 hours in circulation.<ref name=Hohnloser /> Tedisamil is being developed as an alternative to other antiarrhythmics as incidence of additional arrhythmic events is lower compared to other class III agents.<ref name=Hohnloser /> Tedisamil also has significant anti-ischemic properties and was initially investigated as a potential treatment for angina until its antiarrhythmic effects were discovered.<ref name=Fox>{{cite journal|last=Fox|first=K.M.|coauthors=et al.|title=Antianginal and anti-ischemic efficacy of tedisamil, a potassium channel blocker|journal=Heart|year=2000|issue=83|pages=161–171}}</ref>
'''Tedisamil''' (3,7-dicyclopropylmethyl-9,9-tetramethylene-3,7-diazabicyclo-3,3,1-nonane) is an experimental class III [[antiarrhythmic]] agent currently being investigated for the treatment of [[atrial fibrillation]]. Tedisamil blocks multiple types of potassium channels in the heart resulting in slowed heart rate. While the effects of tedisamil have been demonstrated in both atrial and ventricular muscle, repolarization is prolonged more efficiently in the atria.<ref name=Hohnloser>{{cite journal|last=Hohnloser|first=S.H.|coauthors=et al.|title=Safety and Efficacy of Intravenously Administered Tedisamil for Rapid Conversion of Recent-Onset Atrial Fibrillation or Atrial Flutter|journal=Am J Cardiol|year=2004|issue=44|pages=99–104}}</ref> Tedisamil is administered intravenously and has a [[half-life]] of approximately 8 –13 hours in circulation.<ref name=Hohnloser /> Tedisamil is being developed as an alternative to other antiarrhythmics as incidence of additional arrhythmic events is lower compared to other class III agents.<ref name=Hohnloser /> Tedisamil also has significant anti-ischemic properties and was initially investigated as a potential treatment for angina until its antiarrhythmic effects were discovered.<ref name=Fox>{{cite journal|last=Fox|first=K.M.|coauthors=et al.|title=Antianginal and anti-ischemic efficacy of tedisamil, a potassium channel blocker|journal=Heart|year=2000|issue=83|pages=161–171}}</ref>
Line 62: Line 64:


==References==
==References==
{{Reflist|2}}
{{reflist|2}}
 
{{Potassium channel blockers}}{{Antiarrhythmic agents}}


[[Category:Potassium channel blockers]]
{{Antiarrhythmic agents}}
[[Category:Nitrogen heterocycles]]


[[it:Tedisamil]]
[[Category:Antiarrhythmic agents]]
[[pt:Tedisamila]]
[[Category:Cardiovascular Drugs]]
{{WH}}
[[Category:Drug]]
{{WS}}

Latest revision as of 17:13, 20 August 2015

Tedisamil
Clinical data
ATC code
Identifiers
CAS Number
PubChem CID
IUPHAR/BPS
UNII
KEGG
ChEMBL
E number{{#property:P628}}
ECHA InfoCard{{#property:P2566}}Lua error in Module:EditAtWikidata at line 36: attempt to index field 'wikibase' (a nil value).
Chemical and physical data
FormulaC19H32N2
Molar mass288.470 g/mol
3D model (JSmol)
 ☒N☑Y (what is this?)  (verify)

WikiDoc Resources for Tedisamil

Articles

Most recent articles on Tedisamil

Most cited articles on Tedisamil

Review articles on Tedisamil

Articles on Tedisamil in N Eng J Med, Lancet, BMJ

Media

Powerpoint slides on Tedisamil

Images of Tedisamil

Photos of Tedisamil

Podcasts & MP3s on Tedisamil

Videos on Tedisamil

Evidence Based Medicine

Cochrane Collaboration on Tedisamil

Bandolier on Tedisamil

TRIP on Tedisamil

Clinical Trials

Ongoing Trials on Tedisamil at Clinical Trials.gov

Trial results on Tedisamil

Clinical Trials on Tedisamil at Google

Guidelines / Policies / Govt

US National Guidelines Clearinghouse on Tedisamil

NICE Guidance on Tedisamil

NHS PRODIGY Guidance

FDA on Tedisamil

CDC on Tedisamil

Books

Books on Tedisamil

News

Tedisamil in the news

Be alerted to news on Tedisamil

News trends on Tedisamil

Commentary

Blogs on Tedisamil

Definitions

Definitions of Tedisamil

Patient Resources / Community

Patient resources on Tedisamil

Discussion groups on Tedisamil

Patient Handouts on Tedisamil

Directions to Hospitals Treating Tedisamil

Risk calculators and risk factors for Tedisamil

Healthcare Provider Resources

Symptoms of Tedisamil

Causes & Risk Factors for Tedisamil

Diagnostic studies for Tedisamil

Treatment of Tedisamil

Continuing Medical Education (CME)

CME Programs on Tedisamil

International

Tedisamil en Espanol

Tedisamil en Francais

Business

Tedisamil in the Marketplace

Patents on Tedisamil

Experimental / Informatics

List of terms related to Tedisamil

Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1]

Overview

Tedisamil (3,7-dicyclopropylmethyl-9,9-tetramethylene-3,7-diazabicyclo-3,3,1-nonane) is an experimental class III antiarrhythmic agent currently being investigated for the treatment of atrial fibrillation. Tedisamil blocks multiple types of potassium channels in the heart resulting in slowed heart rate. While the effects of tedisamil have been demonstrated in both atrial and ventricular muscle, repolarization is prolonged more efficiently in the atria.[1] Tedisamil is administered intravenously and has a half-life of approximately 8 –13 hours in circulation.[1] Tedisamil is being developed as an alternative to other antiarrhythmics as incidence of additional arrhythmic events is lower compared to other class III agents.[1] Tedisamil also has significant anti-ischemic properties and was initially investigated as a potential treatment for angina until its antiarrhythmic effects were discovered.[2] Tedisamil is manufactured by Solvay Pharmaceuticals Inc. under the proposed trade name Pulzium and is currently in phase III of clinical testing for atrial fibrillation.[3]

Molecular Problem

Arrhythmias are broadly defined as abnormal electrical activity in the heart and can affect both the atria and ventricles. Atrial arrhythmias are the most common type of arrhythmia with several subtypes currently described, including atrial fibrillation. In atrial fibrillation, there is continual quivering of the atria as contraction of the muscle is uncoordinated.[4] Under normal conditions, an electrical impulse from the sinoatrial (SA) node is distributed rapidly throughout the atria causing coordinated excitement and inactivation of atrial muscle cell ion channels resulting in uniform contraction and relaxation of the muscle fibres.[4] During fibrillation, other electrical signals overwhelm the SA node and ion channel excitement is no longer uniform throughout the atria.[4] This results in inappropriate activation properties, further preventing uniform contraction and relaxation of the muscle.[4] Subsequent action potentials from the SA node will not be able to uniformly excite the muscle as not all of the channels will be available to open as some will still be held in the inactivation phase.[4] This results in disjointed contraction, or quivering, seen in the atrial muscle during fibrillation.

Mechanism of Action

Tedisamil acts to restore normal electrical rhythm in the heart by prolonging the inactivation phase of the muscle. Both atrial and ventricular repolarization is lengthened by tedisamil by blocking multiple potassium channels including the transient outward (Ito), the adenosine triphosphate-dependent (IK-ATP), and the delayed rectifier potassium currents (IKr and IKs).[5][6][7] Tedisamil action is dose dependent as currents are blocked longer and more effectively at higher concentrations.[1] Tedisamil activity is greatest on Ito and acts by binding to the channel in its open configuration.[5] This produces a blocked state and delays its inactivation.[5] To restore normal function, tedisamil must unbind from the channel so that it can inactivate and eventually reopen.[5] Similar mechanisms have been observed on the IKr and IKs currents.[6] In both Ito and delayed rectifier channels, the tedisamil binding site appears to be internal as both binding and unbinding occur more effectively when tedisamil is applied inside the cell.[6] Tedisamil also appears to provide specific, single channel blocking of IK-ATP at high concentrations.[7] As the potassium channels are responsible for restoring the resting membrane potential during an action potential, lengthening their inactivation will stop the cycle of fibrillation by preventing muscle contraction until all ion channels are available to open. Regular use of tedisamil will prevent further fibrillation and restore normal electrical rhythm. Tedisamil’s antiarrythmic activity also appears to be supported by inhibiting sodium currents in cardiac muscle.[5] However this is only observed at concentrations above 20μM, concentrations 20-fold higher than required for potassium channel blocks.[5]

References

  1. ↑ 1.0 1.1 1.2 1.3 Hohnloser, S.H. (2004). "Safety and Efficacy of Intravenously Administered Tedisamil for Rapid Conversion of Recent-Onset Atrial Fibrillation or Atrial Flutter". Am J Cardiol (44): 99–104. Unknown parameter |coauthors= ignored (help)
  2. ↑ Fox, K.M. (2000). "Antianginal and anti-ischemic efficacy of tedisamil, a potassium channel blocker". Heart (83): 161–171. Unknown parameter |coauthors= ignored (help)
  3. ↑ Solvay Press Office. "Solvay Pharmaceuticals files Tedisamil, a new cardiometabolic product for the treatment of atrial fibrillation and atrial flutter". Retrieved February 1, 2011.
  4. ↑ 4.0 4.1 4.2 4.3 4.4 Moe, G.K. (1959). "Atrial Fibrillation as a Self-Sustaining Arrhythmia Independent of Focal Discharge". Am Heart J (58): 59–70. Unknown parameter |coauthors= ignored (help)
  5. ↑ 5.0 5.1 5.2 5.3 5.4 5.5 Wettwer, E. (1998). "Mechanism of block by tedisamil of transient outward current in human ventricular subepicardial myocytes". Br J Pharmacol (125): 659–666. Unknown parameter |coauthors= ignored (help)
  6. ↑ 6.0 6.1 6.2 Dukes, I.D. (1990). "Tedisamil blocks the transient and delayed rectifier K+ currents in mammalian cardiac and glial cells". J Clin Pharmacol (254): 560–569. Unknown parameter |coauthors= ignored (help)
  7. ↑ 7.0 7.1 Nemeth, M (1997). "Tedisamil is a potent blocker of ATP-sensitive potassium channels in cardiac muscle". Exp Clin Cardiol (2): 37–40. Unknown parameter |coauthors= ignored (help)

Template:Antiarrhythmic agents

Retrieved from "https://www.wikidoc.org/index.php?title=Tedisamil&oldid=1137613"